Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2025-12-24 @ 11:30 PM
NCT ID:
NCT00002956
Eligibility Criteria:
Inclusion criteria:
* Radiographic evidence of lymphadenopathy or lymphomatous lesions combined with clinical signs of Epstein-Barr virus lymphoproliferative disease (EBV LPD), such as fevers and lymphadenopathy
* following an organ transplant Persistent, progressive, or unresponsive disease despite decreased immunosuppression, chemotherapy, or radiation therapy EBV LPD must be of host origin
* At least 4 weeks
* Patients serologically hepatitis B and C positive may receive cytotoxic
* T- lymphocytes (CTL) from donors who are serologically positive for the same virus
* Must have an HLA identical or HLA haploidentical donor
Exclusion
* hepatic dysfunction SGOT/SGPT less than 2.5 times upper limit of normal (unless liver metastases present)
* Bilirubin less than 2.0 mg/dL
* renal dysfunction
* Creatinine clearance at greater than 50 mL/min
* cardiac dysfunction
* neurologic dysfunction
* pulmonary dysfunction
* patients developing EBV LPD who have a donor origin lymphoma
* HIV-1 positive
* Not capable of undergoing leukapheresis
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00002956
Study Brief:
Protocol Section:
NCT00002956